World Investment Advisors Acquires 1,597 Shares of Elevance Health, Inc. $ELV

World Investment Advisors boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,290 shares of the company’s stock after purchasing an additional 1,597 shares during the period. World Investment Advisors’ holdings in Elevance Health were worth $9,606,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Elevance Health by 0.6% during the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP raised its stake in shares of Elevance Health by 4.8% in the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after acquiring an additional 303,099 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after acquiring an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC raised its stake in shares of Elevance Health by 0.6% in the fourth quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after acquiring an additional 24,271 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Elevance Health by 22.9% in the third quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock valued at $839,300,000 after acquiring an additional 484,303 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

ELV stock opened at $399.32 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a 50 day moving average price of $318.59 and a 200 day moving average price of $333.23. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $412.96. The stock has a market capitalization of $86.72 billion, a PE ratio of 16.98, a price-to-earnings-growth ratio of 2.24 and a beta of 0.66.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the company posted $11.97 EPS. Elevance Health’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ELV. JPMorgan Chase & Co. lifted their target price on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. UBS Group set a $400.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Truist Financial cut their target price on shares of Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, Citigroup upgraded shares of Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $384.58.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.